| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Pediatrics (Dr. Rubin), Wake Forest University School of Medicine, Winston-Salem, NC; and Department of Pulmonary Medicine (Dr. Henke), Philipps-University Marburg, Marburg, Germany.
Correspondence to: Bruce K. Rubin, MD, MEngr, FCCP, Professor and Vice-Chair, Department of Pediatrics, Professor of Biomedical Engineering, Physiology, and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1081; e-mail: brubin{at}wfubmc.edu
The use of troleandomycin as adjunctive therapy for the treatment of patients with corticosteroid-dependent asthma first suggested an immunomodulatory effect of the macrolide antibiotics. This led to studies of the macrolides in other chronic airway diseases, such as diffuse panbronchiolitis (DPB), a disease occurring primarily in East Asia. The use of macrolides for the therapy of patients with DPB has led to dramatic improvements in pulmonary function and prolonged survival. Similar benefits have been documented in Japanese studies of bronchiectasis, chronic bronchitis, and sinobronchial syndrome. Clinical and pathologic similarities between DPB and cystic fibrosis (CF) led to the investigation of macrolides for the treatment of CF. Data now suggest that persons with CF will benefit from macrolide therapy. In vitro and in vivo studies suggest that macrolides may inhibit the pulmonary influx of neutrophils, inhibit the release of proinflammatory cytokines, protect the epithelium from bioactive phospholipids, and improve the transportability of airway secretions. The immunomodulatory effects of the macrolides also may be beneficial for the treatment of other chronic inflammatory conditions.
Key Words: azithromycin • clarithromycin • cystic fibrosis • cytokines • diffuse panbronchiolitis • erythromycin • macrolide antibiotics • neutrophil • troleandomycin
This article has been cited by other articles:
|
|
 |
|
  R. W. Vandivier, P. M. Henson, and I. S. Douglas Burying the Dead: The Impact of Failed Apoptotic Cell Removal (Efferocytosis) on Chronic Inflammatory Lung Disease Chest, June 1, 2006; 129(6): 1673 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yasutomi, Y. Ohshima, N. Omata, A. Yamada, H. Iwasaki, Y. Urasaki, and M. Mayumi Erythromycin Differentially Inhibits Lipopolysaccharide- or Poly(I:C)-Induced but Not Peptidoglycan-Induced Activation of Human Monocyte-Derived Dendritic Cells J. Immunol., December 15, 2005; 175(12): 8069 - 8076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Johnston and R. J. Martin Chlamydophila pneumoniae and Mycoplasma pneumoniae: A Role in Asthma Pathogenesis? Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1078 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Rios, M. Fonseca-Aten, A. Mejias, S. Chavez-Bueno, K. Katz, A. M. Gomez, G. H. McCracken Jr., O. Ramilo, and R. D. Hardy Microbiologic and Immunologic Evaluation of a Single High Dose of Azithromycin for Treatment of Experimental Mycoplasma pneumoniae Pneumonia Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3970 - 3973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wagner, G. Soong, S. Sokol, L. Saiman, and A. Prince Effects of Azithromycin on Clinical Isolates of Pseudomonas aeruginosa From Cystic Fibrosis Patients Chest, August 1, 2005; 128(2): 912 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pallasch, D. L. Brown, L. M. Golub, and J. G. Thomas Subantimicrobial Doses of Tetracycline Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): e163 - e163. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
